These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38577753)
1. Effectiveness of atropine in managing sialorrhea: A systematic review and meta-analysis. Yellepeddi VK; Race JA; McFarland MM; Constance JE; Fanaeian E; Murphy NA Int J Clin Pharmacol Ther; 2024 Jun; 62(6):267-277. PubMed ID: 38577753 [TBL] [Abstract][Full Text] [Related]
2. The effect of sublingual atropine sulfate on clozapine-induced hypersalivation: a multicentre, randomised placebo-controlled trial. Mubaslat O; Lambert T Psychopharmacology (Berl); 2020 Oct; 237(10):2905-2915. PubMed ID: 32876732 [TBL] [Abstract][Full Text] [Related]
3. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Hyson HC; Johnson AM; Jog MS Mov Disord; 2002 Nov; 17(6):1318-20. PubMed ID: 12465075 [TBL] [Abstract][Full Text] [Related]
4. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Dias BLS; Fernandes AR; Maia HS Arq Neuropsiquiatr; 2017 May; 75(5):282-287. PubMed ID: 28591387 [TBL] [Abstract][Full Text] [Related]
5. Sublingual Atropine Administration for Clozapine-Induced Sialorrhea in Bipolar Disorder: A Case Report Highlighting its Efficacy, Safety Concerns and Challenges. Afroz O; Garg S; Kumar A; Kathiresan P; Mishra D; Deep R Psychopharmacol Bull; 2024 Aug; 54(4):124-130. PubMed ID: 39263201 [TBL] [Abstract][Full Text] [Related]
6. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120 [TBL] [Abstract][Full Text] [Related]
7. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins. Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786 [TBL] [Abstract][Full Text] [Related]
8. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Young CA; Ellis C; Johnson J; Sathasivam S; Pih N Cochrane Database Syst Rev; 2011 May; (5):CD006981. PubMed ID: 21563158 [TBL] [Abstract][Full Text] [Related]
9. Salivary gland application of botulinum toxin for the treatment of sialorrhea. Fuster Torres MA; Berini Aytés L; Gay Escoda C Med Oral Patol Oral Cir Bucal; 2007 Nov; 12(7):E511-7. PubMed ID: 17978775 [TBL] [Abstract][Full Text] [Related]
10. Salivation in Parkinson's disease: A scoping review. Verhoeff MC; Koutris M; Vries R; Berendse HW; Dijk KDV; Lobbezoo F Gerodontology; 2023 Mar; 40(1):26-38. PubMed ID: 35246869 [TBL] [Abstract][Full Text] [Related]
11. Evaluation and Comparison of the Effectiveness of Atropine Eye Drops, Ipratropium Bromide Nasal Spray, and Amitriptyline Tablet in the Management of Clozapine-Associated Sialorrhea in Patients With Refractory Schizophrenia: A Randomized Clinical Trial. Mohammad-Gholizad F; Karimzadeh I; Moghimi-Sarani E; Arshadi M; Mortazavi N J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):9-15. PubMed ID: 38100776 [TBL] [Abstract][Full Text] [Related]
12. Does Botulinum neurotoxin type A treatment for sialorrhea change oral health? Tiigimäe-Saar J; Taba P; Tamme T Clin Oral Investig; 2017 Apr; 21(3):795-800. PubMed ID: 27114092 [TBL] [Abstract][Full Text] [Related]